Newsfile Corp
29 Sept 2026, 07:30 UTC · 7w ago
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Impact · against what's priced in
Telo Genomics demonstrates a potential competitive advantage over Adaptive Biotechnologies by identifying circulating plasma cells in patients who were non-evaluable by clonoSEQ due to lack of a dominant clone. While the data is based on a limited research set, it suggests an expanded addressable market for TELO's blood-based approach compared to bone-marrow NGS.
- TELO+0.60
No priced-in read yet





